April 11 (Bloomberg) -- Hospira Inc.’s U.K. unit won a
court ruling overturning two patents for Roche Holding AG’s top-selling breast-cancer drug Herceptin, paving the way for the
generic drug-maker to sell a cheaper competitor in the country.
The primary patent on Herceptin expires on July 28 in
Europe. Lake Forest, Illinois-based Hospira was seeking to
invalidate two additional protections that relate to the dosages
and composition of the drug.